Fuzuloparib as maintenance therapy among patients with advanced ovarian cancer after a response to first-line platinum-based chemotherapy: Results from a randomized, placebo-controlled, phase III trial
机构:[1]PUMC, Nat Canc Ctr, Canc Hosp, Chinese Acad Med Sci, Beijing, Peoples R China[2]Hunan Canc Hosp, Changsha, Peoples R China[3]Shandong First Med Univ, Affiliated Canc Hosp, Shandong, Peoples R China[4]China Med Univ, Canc Hosp, Liaoning Canc Hosp & Inst, Shenyang, Peoples R China[5]Chongqing Med Univ, Affiliated Hosp 1, Chongqing, Peoples R China重庆医科大学附属第一医院[6]Inner Mongolia Peoples Hosp, Hohhot, Peoples R China[7]Sichuan Canc Hosp, Chengdu, Peoples R China四川省肿瘤医院[8]Shanxi Med Univ, Hosp 2, Taiyuan, Peoples R China[9]Guangxi Med Univ, Canc Hosp, Nanning, Peoples R China[10]Capital Med Univ, Beijing Obstet & Gynecol Hosp, Beijing, Peoples R China[11]HUST, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China华中科技大学同济医学院附属同济医院[12]Henan Canc Hosp, Zhengzhou, Peoples R China河南省肿瘤医院[13]Shandong Univ, Qilu Hosp, Jinan, Peoples R China[14]Xi An Jiao Tong Univ, Affiliated Hosp 1, Xian, Peoples R China[15]Sichuan Univ, West China Hosp 2, Chengdu, Peoples R China[16]Chongqing Univ, Canc Hosp, Chongqing, Peoples R China[17]Kunming Med Univ, Yunnan Canc Hosp, Affiliated Hosp 3, Kunming, Yunnan, Peoples R China[18]Zhejiang Canc Hosp, Hangzhou, Peoples R China浙江省肿瘤医院[19]Dalian Med Univ, Hosp 2, Dalian, Peoples R China[20]Jiangsu Canc Hosp, Nanjing, Peoples R China[21]Anhui Prov Hosp, Hefei, Peoples R China[22]Hubei Canc Hosp, Wuhan, Peoples R China[23]Anhui Prov Canc Ctr, Hefei, Peoples R China[24]Jiangsu Hengrui Pharmaceut Co Ltd, Shanghai, Peoples R China
第一作者机构:[1]PUMC, Nat Canc Ctr, Canc Hosp, Chinese Acad Med Sci, Beijing, Peoples R China
推荐引用方式(GB/T 7714):
Wu Lingying,Li Ning,Wang Jing,et al.Fuzuloparib as maintenance therapy among patients with advanced ovarian cancer after a response to first-line platinum-based chemotherapy: Results from a randomized, placebo-controlled, phase III trial[J].GYNECOLOGIC ONCOLOGY.2024,190:S74-S75.
APA:
Wu, Lingying,Li, Ning,Wang, Jing,Li, Qingshui,Wang, Danbo...&Li, Bo.(2024).Fuzuloparib as maintenance therapy among patients with advanced ovarian cancer after a response to first-line platinum-based chemotherapy: Results from a randomized, placebo-controlled, phase III trial.GYNECOLOGIC ONCOLOGY,190,
MLA:
Wu, Lingying,et al."Fuzuloparib as maintenance therapy among patients with advanced ovarian cancer after a response to first-line platinum-based chemotherapy: Results from a randomized, placebo-controlled, phase III trial".GYNECOLOGIC ONCOLOGY 190.(2024):S74-S75